Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.
Mari HosonagaEri HabanoHiromi ArakawaKeika KanekoTakeshi NakajimaNaomi HayashiIppei FukadaAkira NakamuraYurie HaruyamaTetsuyo MaedaHitoshi InariTakayuki KobayashiEri NakashimaTakayuki UenoToshimi TakanoShunji TakahashiShinji OhnoArisa UekiPublished in: Breast cancer (Tokyo, Japan) (2024)
The occurrence of HER2 + breast cancer subtype was 40% in our LFS case series, which is greater than that in the general population (16-25%). Some TP53 PVs may facilitate HER2-derived oncogenesis in breast cancer. However, further studies with larger sample sizes are warranted to clarify the oncogenic mechanisms underlying each subtype of breast cancer in TP53 PV carriers.
Keyphrases